...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Biopreservation and biobanking >Specimen quality evaluation in canadian biobanks participating in the COEUR repository
【24h】

Specimen quality evaluation in canadian biobanks participating in the COEUR repository

机译：参与COEUR存储库的加拿大生物库中的标本质量评估

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Human biological specimens are important for translational research programs such as the Canadian Ovarian Experimental Unified Resource (COEUR) funded by the Terry Fox Research Institute. Sample quality is an important consideration, as it directly impacts the quality of ensuing research. The aim of the present study was to determine the quality of tissues collected from different sites contributing to the COEUR cohort. Samples from high-grade serous ovarian tumors (fresh frozen and corresponding paraffin-embedded tissues) were provided by nine participating Canadian biobanks. All samples were shipped to a central site using a Standard Operating Protocol (SOP). DNA and RNA extraction was conducted by the quality control division of the Canadian Tumor Repository Network (CTRNet). DNA quality was determined by ?-globin gene PCR amplification, and RNA quality by the RNA integrity number (RIN), as measured by the Agilent BioAnalyzer. DNA of acceptable quality had at least three bands of ?-globin amplified from DNA (n = 115/135), and a RIN number ? 7 was considered very good for RNA (n = 80/135). Sample preparation and storage time had little effect on RNA or DNA quality. Protein expression was assessed on tissue microarray by immunohistochemistry with antibodies against p53, WT1, E-cadherin, CK-7, and Ki67 from formalin fixed-paraffin embedded (FFPE) tissues. As seen with a nonhierarchical clustering statistical method, there was no significant difference in immunostaining of paraffin tissues among specimens from different biobanks. Interestingly, patients with worse outcome were highly positive for p53 and weak for WT1. In conclusion, while there was no common SOP for retrospectively collected material across Canadian biobanks, these results indicate that specimens collected at these multiple sites are of comparable quality, and can serve as an adequate resource to create a national cohort for the validation of molecular biomarkers in ovarian cancer.
机译：人体生物学标本对于转化研究计划（例如由特里·福克斯研究所资助的加拿大卵巢实验统一资源（COEUR））非常重要。样品质量是一个重要的考虑因素，因为它直接影响后续研究的质量。本研究的目的是确定从有助于COEUR队列的不同部位收集的组织的质量。来自九个参与的加拿大生物库提供了来自高级浆液性卵巢肿瘤（新鲜冷冻和相应的石蜡包埋组织）的样品。使用标准操作协议（SOP）将所有样品运送到中央站点。 DNA和RNA的提取是由加拿大肿瘤知识库网络（CTRNet）的质量控制部门进行的。 DNA质量通过β-珠蛋白基因PCR扩增来确定，RNA质量通过RNA完整性数（RIN）来确定，如Agilent BioAnalyzer所测量。质量合格的DNA从DNA扩增出至少3条β珠蛋白带（n = 115/135），并且RIN数≥ 7被认为对RNA非常好（n = 80/135）。样品制备和保存时间对RNA或DNA的质量影响很小。通过免疫组织化学用来自福尔马林固定石蜡包埋的（FFPE）组织的针对p53，WT1，E-钙粘着蛋白，CK-7和Ki67的抗体进行免疫组织化学评估，在组织微阵列上表达蛋白质。如使用非分层聚类统计方法所见，来自不同生物库的标本在石蜡组织的免疫染色方面没有显着差异。有趣的是，预后较差的患者p53阳性，而WT1弱。总而言之，尽管加拿大生物库中没有可追溯收集的通用SOP，但这些结果表明，在多个地点收集的标本质量相当，可以作为建立分子生物学标记验证国家队列的足够资源。在卵巢癌中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号